Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder

The treatment portion of this study consists of a 40 minute TMS session 5 days a week (Mon-Fri) for 6 weeks.  Other visits include an intake assessment, a pre-treatment MRI, a post-treatment assessment and MRI, and a 6 month follow up visit.  Participants are paid for both MRI visits, the post-treatment visit and the follow up visit.  Half of participants will receive real TMS, while the other half will receive sham (placebo) TMS.

Hartford Hospital’s Institute of Living, Yale University School of Medicine
Principal Investigator: 
Gretchen Diefenbach, PhD
Eligibility Criteria: 

Individuals with the following will be considered for this study:


  • Diagnosed with GAD as the principal or co-principal disorder
  • Clinical Global Impression Score ≥ 4
  • Hamilton Anxiety Rating Scale ≥ 18
  • Hamilton Rating Scale for Depression ≤ 17
  • Fluency in English
  • Capacity to understand the nature of the study and willingness to sign informed consent form
Exclusion Criteria: 

Individuals with the following will not be considered for the study:


  • History of epilepsy or head trauma (LOC > 5 minutes) within the past 6 months. Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis, or brain surgery
  • A review of patient medications by the study physician indicates an increased risk of seizure
  • An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency
  • Substance use disorder or post traumatic stress disorder within the past 6 months. Lifetime obsessive-compulsive disorder,bipolar disorder, psychotic disorder, mental retardation, or pervasive developmental disorder. Any psychotic features, including dementia or delirium
  • Concurrent psychotherapy and unwillingness to discontinue
  • Medication change within past 3 months
  • Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months
  • Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study
  • Any contraindication for participation in MRI scan
Laura Bragdon, 860-545-7386,
Hartford, CT
Study End Date: 
Sun, 2014-06-01

Contact ADAA

8701 Georgia Ave., Suite #412
Silver Spring, MD 20910


Contact ADAA

Request Publications



ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, depression, OCD, PTSD, and related disorders and to improving the lives of all people who suffer from them through education, practice, and research.


Privacy Policy 
© ADAA, 2010-2015